Side Letter No. 4: 04 September 2013, by and between Glaxo Group Ltd, Ospedale San Raffaele Srl, and Fondazione Telethon, re: Extension of Option Exercise Period for MLD Program;
Side Letter No. 7: 30 August 2014, by and between GlaxoSmithKline Research and Development Limited (an Affiliate of Glaxo Group Ltd), Ospedale San Raffaele Srl, and Fondazione Telethon, re: Reimbursement of vector production batches and cell processing treatments costs for WAS patients [***] for treatment of such patients following GSK option exercise and prior to GSK’s execution of agreements with MolMed to cover such costs.
Side Letter No. 9: 9 February 2015, by and between GlaxoSmithKline Research and Development Limited (an Affiliate of Glaxo Group Ltd), Ospedale San Raffaele Srl, and Fondazione Telethon, re: Reimbursement of vector production batches and cell processing treatments costs for WAS additional patient.
Side Letter No. 1: [***];
Side Letter No. 2: [***];
Side Letter No. 4: [***];
Side Letter No. 6: [***]; and
Side Letter No. 5: [***]; *** Confidential Treatment Requested *** 148
Side Letter No. 1: 26 June 2012, by and between Glaxo Group Ltd, and Fondazione Telethon, re: Addition of [***] additional patients in the Metachromatic Leukodystrophy Clinical Study (patients [***]);
Side Letter No. 2: 11 June 2013, by and between Glaxo Group Ltd, Ospedale San Raffaele Srl, and Fondazione Telethon, re: Expansion of GLP Facilities;
